Companies / Enliven Therapeutics, Inc. / Activity
Activity — Enliven Therapeutics, Inc.
54 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $35.72M | -787K -10.65% | 6,601,878 9.01% of shares | high |
| Jun 15, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $12.26M | -272K -3.55% | 7,388,902 10.08% of shares | high |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $2.10M | -47K -0.71% | 6,555,102 8.95% of shares | medium |
| Jan 9, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $1.46M | -50K -6.13% | 765,188 1.04% of shares | medium |
| Mar 25, 2026 | Collins Helen Louise Executive | Sell | Common Stock | $1.40M | -40K -61.54% | 25,000 0.03% of shares | medium |
| Jan 9, 2026 | Patel Anish Executive | Sell | Common Stock | $1.34M | -48K -18.25% | 215,254 0.29% of shares | medium |
| Feb 17, 2026 | Collins Helen Louise Executive | Sell | Common Stock | $1.18M | -45K -64.29% | 25,000 0.03% of shares | medium |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $1.13M | -25K -10.11% | 220,882 0.30% of shares | medium |
| Jan 9, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $1.03M | -41K -4.81% | 815,188 1.11% of shares | medium |
| Mar 9, 2026 | Collins Helen Louise Executive | Sell | Common Stock | $896.8K | -30K -54.44% | 25,000 0.03% of shares | medium |
| Jan 8, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $842.5K | -34K -3.80% | 856,386 1.17% of shares | medium |
| Jun 15, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $409.1K | -9K -3.57% | 245,728 0.34% of shares | medium |
| Jan 20, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $390.3K | -15K -1.91% | 745,188 1.02% of shares | medium |
| Mar 10, 2026 | Collins Helen Louise Executive | Sell | Common Stock | $305.8K | -10K -28.83% | 25,000 0.03% of shares | medium |
| Mar 6, 2026 | Hohl Benjamin Executive | Sell | Common Stock | $295.8K | -10K -16.39% | 51,000 0.07% of shares | medium |
| Jan 8, 2026 | Heyman Richard A. Director | Sell | Common Stock | $200.7K | -8K -21.43% | 29,392 0.04% of shares | medium |
| Jan 8, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $151.0K | -8K -0.84% | 890,188 1.21% of shares | medium |
| Feb 6, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $145.2K | -5K -0.67% | 740,188 1.01% of shares | medium |
| Jan 20, 2026 | Lyssikatos Joseph P Executive | Sell | Common Stock | $144.8K | -5K -0.72% | 759,697 1.04% of shares | medium |
| Mar 17, 2026 | Collins Helen Louise Executive | Sell | Common Stock | $138.8K | -5K -16.67% | 25,000 0.03% of shares | medium |
| Feb 17, 2026 | Collins Helen Louise Executive | Exercise | Common Stock | $111.6K | +45K +180.00% | 70,000 0.10% of shares | low |
| Jan 9, 2026 | Heyman Richard A. Director | Sell | Common Stock | $107.1K | -4K -14.58% | 25,107 0.03% of shares | medium |
| Mar 25, 2026 | Collins Helen Louise Executive | Exercise | Common Stock | $99.2K | +40K +160.00% | 65,000 0.09% of shares | low |
| Mar 9, 2026 | Collins Helen Louise Executive | Exercise | Common Stock | $74.1K | +30K +119.48% | 54,871 0.07% of shares | low |
| Jun 22, 2026 | Orbimed Advisors LLC 10% owner | Sell | Common Stock | $66.5K | -1K -0.67% | 219,405 0.30% of shares | low |
| Jan 8, 2026 | Heyman Richard A. Director | Sell | Common Stock | $40.5K | -2K -5.96% | 25,545 0.03% of shares | low |
| Feb 17, 2026 | Heyman Richard A. Director | Sell | Common Stock | $32.2K | -1K -5.15% | 22,647 0.03% of shares | low |
| Mar 10, 2026 | Collins Helen Louise Executive | Exercise | Common Stock | $25.1K | +10K +40.52% | 35,129 0.05% of shares | low |
| Jan 20, 2026 | Heyman Richard A. Director | Sell | Common Stock | $19.4K | -718 -2.92% | 23,877 0.03% of shares | low |
| Jan 20, 2026 | Heyman Richard A. Director | Sell | Common Stock | $13.5K | -512 -2.04% | 24,595 0.03% of shares | low |
| Mar 17, 2026 | Collins Helen Louise Executive | Exercise | Common Stock | $12.4K | +5K +20.00% | 30,000 0.04% of shares | low |
| Jan 9, 2026 | Patel Anish Executive | Sell | Common Stock | $6.9K | -243 -0.11% | 215,011 0.29% of shares | low |
| Feb 12, 2026 | Collins Helen Louise Executive | Grant | Common Stock | $0 | +25K | 25,000 0.03% of shares | low |
| Feb 12, 2026 | Patel Anish Executive | Grant | Common Stock | $0 | +20K | 20,000 0.03% of shares | low |
| Feb 12, 2026 | Lyssikatos Joseph P Executive | Grant | Common Stock | $0 | +19K | 18,750 0.03% of shares | low |
| Feb 12, 2026 | Hohl Benjamin Executive | Grant | Common Stock | $0 | +25K +69.44% | 61,000 0.08% of shares | low |
| Mar 25, 2026 | Collins Helen Louise Executive | Exercise | Stock Option (right to buy) | — | -40K -22.69% | 136,268 0.19% of shares | low |
| Feb 12, 2026 | Ballal Rahul D. Director | Grant | Stock Option (right to buy) | — | +17K | 17,126 0.02% of shares | low |
| Mar 17, 2026 | Collins Helen Louise Executive | Exercise | Stock Option (right to buy) | — | -5K -2.76% | 176,268 0.24% of shares | low |
| Mar 10, 2026 | Collins Helen Louise Executive | Exercise | Stock Option (right to buy) | — | -10K -5.29% | 181,268 0.25% of shares | low |
| Mar 9, 2026 | Collins Helen Louise Executive | Exercise | Stock Option (right to buy) | — | -30K -13.50% | 191,397 0.26% of shares | low |
| Feb 17, 2026 | Collins Helen Louise Executive | Exercise | Stock Option (right to buy) | — | -45K -16.90% | 221,268 0.30% of shares | low |
| Feb 12, 2026 | Collins Helen Louise Executive | Grant | Stock Option (right to buy) | — | +150K | 150,000 0.20% of shares | low |
| Feb 12, 2026 | Patel Anish Executive | Grant | Stock Option (right to buy) | — | +120K | 120,000 0.16% of shares | low |
| Feb 12, 2026 | Lyssikatos Joseph P Executive | Grant | Stock Option (right to buy) | — | +113K | 112,500 0.15% of shares | low |
| Feb 12, 2026 | Hohl Benjamin Executive | Grant | Stock Option (right to buy) | — | +150K | 150,000 0.20% of shares | low |
| Feb 12, 2026 | Derynck Mika K Director | Grant | Stock Option (right to buy) | — | +17K | 17,126 0.02% of shares | low |
| Feb 12, 2026 | Bauer Jake Director | Grant | Stock Option (right to buy) | — | +17K | 17,126 0.02% of shares | low |
| Feb 12, 2026 | Heyman Richard A. Director | Grant | Stock Option (right to buy) | — | +19K | 19,234 0.03% of shares | low |
| Feb 12, 2026 | Gupta Rishi Director | Grant | Stock Option (right to buy) | — | +2K | 1,580 <0.01% of shares | low |